252 related articles for article (PubMed ID: 29533116)
21. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
22. Clinical remission of psoriatic arthritis in patients receiving continuous biological therapies for 1 year: the experience of an outpatient dermatological clinic for psoriasis.
Graceffa D; Maiani E; Sperduti I; Ceralli F; Bonifati C
Clin Exp Dermatol; 2015 Mar; 40(2):136-41. PubMed ID: 25438647
[TBL] [Abstract][Full Text] [Related]
23. Biologics in Inflammatory and Immunomediated Arthritis.
Luchetti MM; Benfaremo D; Gabrielli A
Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
[TBL] [Abstract][Full Text] [Related]
24. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
25. Progress of biological agents on psoriatic arthritis.
Li Y; Wang D; Wang Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):525-34. PubMed ID: 25213361
[TBL] [Abstract][Full Text] [Related]
26. Novel approaches to biological therapy for psoriatic arthritis.
Boyd T; Kavanaugh A
Expert Opin Biol Ther; 2016; 16(2):173-86. PubMed ID: 26572089
[TBL] [Abstract][Full Text] [Related]
27. Small molecule therapy for managing moderate to severe psoriatic arthritis.
Costa L; Del Puente A; Peluso R; Tasso M; Caso P; Chimenti MS; Sabbatino V; Girolimetto N; Benigno C; Bertolini N; Del Puente A; Perricone R; Scarpa R; Caso F
Expert Opin Pharmacother; 2017 Oct; 18(15):1557-1567. PubMed ID: 28891341
[TBL] [Abstract][Full Text] [Related]
28. Emerging drugs for psoriatic arthritis.
Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L
Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876
[TBL] [Abstract][Full Text] [Related]
29. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
30. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
Abdulrahim H; Thistleton S; Adebajo AO; Shaw T; Edwards C; Wells A
Expert Opin Pharmacother; 2015 May; 16(7):1099-108. PubMed ID: 25864487
[TBL] [Abstract][Full Text] [Related]
31. Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis.
Tillett W; Shaddick G; Jobling A; Askari A; Cooper A; Creamer P; Clunie G; Helliwell PS; James J; Kay L; Korendowych E; Lane S; Packham J; Shaban R; Thomas ML; Williamson L; McHugh N
Rheumatology (Oxford); 2017 Apr; 56(4):603-612. PubMed ID: 28013211
[TBL] [Abstract][Full Text] [Related]
32. Beyond anti-TNF-α agents in psoriatic arthritis.
Spadaro A; Lubrano E
Expert Rev Clin Immunol; 2013 Jun; 9(6):507-9. PubMed ID: 23730881
[TBL] [Abstract][Full Text] [Related]
33. Apremilast for the treatment of psoriatic arthritis.
Souto A; Gómez-Reino JJ
Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
[TBL] [Abstract][Full Text] [Related]
34. Sex Differences in the Treatment of Psoriatic Arthritis: A Systematic Literature Review.
Generali E; Sciré CA; Cantarini L; Selmi C
Isr Med Assoc J; 2016; 18(3-4):203-8. PubMed ID: 27228644
[TBL] [Abstract][Full Text] [Related]
35. Therapies for dactylitis in psoriatic arthritis. A systematic review.
Helliwell PS
J Rheumatol; 2006 Jul; 33(7):1439-41. PubMed ID: 16724369
[TBL] [Abstract][Full Text] [Related]
36. Difficult to treat psoriatic arthritis - how should we manage?
Kumthekar A; Ashrafi M; Deodhar A
Clin Rheumatol; 2023 Sep; 42(9):2251-2265. PubMed ID: 37097525
[TBL] [Abstract][Full Text] [Related]
37. Biologic therapy of psoriatic arthritis.
Gladman DD
Reumatismo; 2007; 59 Suppl 1():85-7. PubMed ID: 17828353
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor inhibitors in psoriatic arthritis.
Mantravadi S; Ogdie A; Kraft WK
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):899-910. PubMed ID: 28490202
[TBL] [Abstract][Full Text] [Related]
39. A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy.
Sachdeva M; Abduelmula A; Mufti A; Georgakopoulos JR; Lytvyn Y; Yeung J
J Cutan Med Surg; 2022; 26(4):414-419. PubMed ID: 35317662
[TBL] [Abstract][Full Text] [Related]
40. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
